0001104659-19-023845.txt : 20190426 0001104659-19-023845.hdr.sgml : 20190426 20190426070025 ACCESSION NUMBER: 0001104659-19-023845 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20190426 FILED AS OF DATE: 20190426 DATE AS OF CHANGE: 20190426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zealand Pharma A/S CENTRAL INDEX KEY: 0001674988 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38178 FILM NUMBER: 19769323 BUSINESS ADDRESS: STREET 1: SMEDELAND 36 STREET 2: 2600 GLOSTRUP CITY: COPENHAGEN STATE: G7 ZIP: 00000 BUSINESS PHONE: 4588773600 MAIL ADDRESS: STREET 1: SMEDELAND 36 STREET 2: 2600 GLOSTRUP CITY: COPENHAGEN STATE: G7 ZIP: 00000 6-K 1 a19-8906_16k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 6-K

 


 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

April 26, 2019

 


 

Commission File Number: 001 - 38178

 


 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 


 

Smedeland 36

2600 Glostrup (Copenhagen)

Denmark

(Address of principal executive offices)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x          Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated April 17, 2019, announcing amendments to the Company’s Articles of Association following the recent grant of warrants to the Company’s employees.

 

Furnished as Exhibit 3.1 to this Report on Form 6-K are the updated Articles of Association of Zealand Pharma A/S, or the Company.

 

 

 


 

Exhibits

 

Reference is made to the Exhibit Index included hereto.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Zealand Pharma A/S

 

 

 

 

By:

/s/ Ivan M. Møller

 

 

 

 

 

Name:

Ivan M. Møller

 

 

Title:

Interim Chief Financial Officer

 

 

 

 

Date: April 26, 2019

 

 

 

 

3


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

 

 

 

3.1

 

Articles of Association.

 

 

 

99.1

 

Company announcement dated April 17, 2019

 

4


EX-3.1 2 a19-8906_1ex3d1.htm EX-3.1

Exhibit 3.1

 

VEDTÆGTER

ARTICLES OF ASSOCIATION

ZEALAND PHARMA A/S

ZEALAND PHARMA A/S

 


 

VEDTÆGTER

ARTICLES OF ASSOCIATION

ZEALAND PHARMA A/S
(CVR-nr.: 20 04 50 78)

ZEALAND PHARMA A/S
(CVR no.: 20 04 50 78)

 

1                           Navn

 

Name

 

 

 

1.1                 Selskabets navn er Zealand Pharma A/S.

 

The Company’s name is Zealand Pharma A/S.

 

 

 

1.2                 Selskabets binavn er Zealand Pharmaceuticals A/S.

 

The Company’s secondary name is Zealand Pharmaceuticals A/S.

 

 

 

2                           Formål

 

Objects

 

 

 

2.1                 Selskabets formål er at drive forskning, produktion, handel og dermed beslægtet virksomhed, primært inden for medicinalbranchen.

 

The object of the Company is to engage in research, manufacture, trade and related activities, primarily within the pharmaceutical industry.

 

 

 

3                           Koncernsprog

 

Corporate language

 

 

 

3.1                 Selskabets koncernsprog er engelsk.

 

The corporate language of the Company is English.

 

 

 

4                           Aktiekapital

 

Share Capital

 

 

 

4.1                 Selskabets aktiekapital udgør DKK 31.679.936.

 

The share capital of the Company is DKK 31,679,936.

 

 

 

4.2                 Aktiekapitalen er fuldt indbetalt.

 

The share capital has been paid up in full.

 

 

 

5                           Aktier

 

Shares

 

 

 

5.1                 Hver akties pålydende er DKK 1.

 

The nominal amount of each share is DKK 1.

 

 

 

5.2                 Aktierne er udstedt gennem VP Securities A/S.

 

The shares are issued through VP Securities A/S.

 

 

 

5.3                 Aktierne er omsætningspapirer.

 

The shares are negotiable instruments.

 

 

 

5.4                 Ingen aktier har særlige rettigheder.

 

No shares carry any special rights.

 


 

5.5                 Der gælder ingen indskrænkninger i aktiernes omsættelighed.

 

No restrictions shall apply as to the transferability of the shares.

 

 

 

5.6                 Ingen aktionær skal være forpligtet til at lade sine aktier indløse helt eller delvist.

 

No shareholder shall be obliged to have the shares redeemed fully or partly.

 

 

 

5.7                 Aktierne udstedes på navn og skal noteres i Selskabets ejerbog.

 

The shares shall be issued in the holder’s name and shall be registered in the Company’s Register of Shareholders.

 

 

 

5.8                 Selskabets ejerbog føres af Computershare A/S, CVR-nr. 27 08 88 99, der er valgt som ejerbogsfører på Selskabets vegne.

 

The Register of Shareholders is handled by Computershare A/S, CVR no. 27 08 88 99, on behalf of the Company.

 

 

 

6                           Udbytte

 

Dividend

 

 

 

6.1                 Udbytte betales til aktionærerne ved overførsel gennem VP Securities A/S.

 

Dividend shall be paid out to shareholders by transfer through VP Securities A/S.

 

 

 

6.2                 Udbytte, der ikke har været hævet inden tre år fra forfaldsdagen, tilfalder Selskabet.

 

Dividend that has not been claimed within three years of the due date shall accrue to the Company.

 

 

 

7                           Bemyndigelse til kapitalforhøjelse

 

Authorization to increase the share capital

 

 

 

7.1                 Bestyrelsen er i perioden indtil den 19. april 2023 bemyndiget til ad en eller flere gange at forhøje Selskabets aktiekapital ved udstedelse af nye aktier med indtil nominelt DKK 6.150.265. Forhøjelsen af aktiekapitalen skal ske til markedskurs og skal gennemføres uden fortegningsret for Selskabets eksisterende aktionærer. Bestyrelsen kan bestemme, at forhøjelsen skal ske ved kontant indbetaling, apportindskud eller ved konvertering af gæld.

 

During the period until 19 April 2023 the board of directors is authorized to increase at one or more times the Company’s share capital by issuance of new shares of up to nominally DKK 6,150,265. The capital increase shall be effected at market price and shall be implemented without pre-emption rights for the Company’s existing shareholders. The board of directors may decide to implement the capital increase by way of cash contribution, by contribution in kind or by debt conversion.

 

 

 

 

 

By decision of 20 March 2019, the

 


 

Ved beslutning af 20. marts 2019, besluttede bestyrelsen at delvist udnytte bemyndigelsen i vedtægternes punkt 7.1 og forhøje aktiekapitalen med nominelt DKK 802.859. Herefter udestår der DKK 5.347.406 under bemyndigelsen.

 

Board of Directors has partly exercised the authority in this article 7.1 to increase the share capital by nominally DKK 802,859. The remaining amount of the authorization is thus DKK 5,347,406.

 

 

 

7.2                 Bestyrelsen er i perioden indtil den 19. april 2023 bemyndiget til ad en eller flere gange at forhøje Selskabets aktiekapital ved udstedelse af nye aktier med indtil nominelt DKK 6.150.265. Forhøjelsen af aktiekapitalen skal gennemføres med fortegningsret for Selskabets eksisterende aktionærer, og den kan ske til en favørkurs fastsat af bestyrelsen. Bestyrelsen kan bestemme, at forhøjelsen skal ske ved kontant indbetaling, apportindskud eller ved konvertering af gæld.

 

During the period until 19 April 2023 the board of directors is authorized to increase at one or more times the Company’s share capital by issuance of new shares by up to nominally DKK 6,150,265. The capital increase shall be implemented with pre-emption rights for the Company’s existing shareholders and the subscription price may be a favourable price fixed by the board of directors of the Company. The board of directors may decide to implement the capital increase by way of cash contribution, by contribution in kind or by debt conversion.

 

 

 

7.3                 De kapitalforhøjelser, som bestyrelsen er bemyndiget til at foretage i henhold til punkt 7.1 og 7.2, kan ikke overstige et samlet nominelt beløb på DKK 6.150.265.

 

The capital increases which the board of directors may decide upon pursuant to articles 7.1 and 7.2 cannot exceed a total aggregate nominal amount of DKK 6,150,265.

 

 

 

7.4                 De nye aktier udstedt i henhold til punkt 7.1 og 7.2 skal være ligestillet med den bestående aktiekapital. De nye aktier skal være omsætningspapirer og navneaktier og skal noteres i Selskabets ejerbog. Ingen aktionær skal være forpligtet til at lade sine aktier indløse helt eller delvist. De nye aktier skal give ret til udbytte og andre rettigheder i Selskabet fra det tidspunkt, som fastsættes af bestyrelsen i forhøjelsesbeslutningen.

 

The new shares issued pursuant to articles 7.1 and 7.2 shall have the same rights as the existing shares of the Company. The new shares shall be negotiable instruments and issued in the holder’s name and shall be registered in the Company’s Register of Shareholders. No shareholder shall be obliged to have the shares redeemed fully or partly. The new shares shall give rights to dividends and other rights in the Company from the time which is determined by the board of directors in connection with the decision to increase the share capital.

 

 

 

 


 

7.5                 Bestyrelsen er bemyndiget til at fastsætte de nærmere vilkår for kapitalforhøjelser i henhold til ovennævnte bemyndigelser. Bestyrelsen er endvidere bemyndiget til at foretage de ændringer i vedtægterne som måtte være nødvendige som følge af bestyrelsens udnyttelse af ovenstående bemyndigelser.

 

The board of directors is authorized to stipulate detailed terms and conditions governing capital increases under the authority given above. The board of directors is also authorized to amend these Articles of Association as required in connection with its use of such authority.

 

 

 

8                           Bemyndigelse til udstedelse af warrants

 

Authorization to issuance of warrants

 

 

 

8.1                 På et bestyrelsesmøde i Selskabet afholdt den 1. april 2014 vedtog Selskabets bestyrelse at udstede warrants (2014-1 employee incentive program) i henhold til bemyndigelse, som udløb den 2. november 2015, svarende til nominelt DKK 100.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed, i henhold til bemyndigelse, som udløb den 2. november 2015. Det konkrete antal warrants tildelt udgør 100.000. De fuldstændige vilkår for warrants er vedlagt som 8.1.f. Bilag 8.1.f udgør en integreret del af nærværende vedtægter. 28.000 warrants er udnyttet den 14. december 2018 og 72.000 warrants er udnyttet den 15. marts 2019, og hermed er alle warrants udnyttet.

 

At a meeting of the board of directors of the Company held on 1 April 2014, the board of directors of the Company resolved to issue warrants (2014-1 employee incentive program) pursuant to an authorization which expired on 2 November 2015, corresponding to a nominal amount of DKK 100,000 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith pursuant to an authorization which expired on 2 November 2015. The final number of warrants granted is 100,000. The complete terms of the warrants are attached as Schedule 8.1.f. Schedule 8.1.f constitutes an integrated part of these Articles of Association. 28,000 warrants were exercised on 14 December 2018 and 72,000 warrants were exercised on 15 March 2019, and thus all warrants were exercised.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 25. marts 2015 vedtog Selskabets bestyrelse at udstede warrants (2015-1 employee incentive program) i henhold til bemyndigelse, som udløb den 2. november 2015, svarende til nominelt DKK 100.000

 

At a meeting of the board of directors of the Company held on 25 March 2015, the board of directors of the Company resolved to issue warrants (2015-1 employee incentive program) pursuant to an authorization which expired on 2 November 2015,

 


 

aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed i henhold til bemyndigelse, som udløb den 2. november 2015. Det konkrete antal warrants tildelt udgør 100.000. De fuldstændige vilkår for warrants er vedlagt som bilag 8.1.g. Bilag 8.1.g udgør en integreret del af nærværende vedtægter.

 

corresponding to a nominal amount of DKK 100,000 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith pursuant to an authorization which expired on 2 November 2015. The final number of warrants granted is 100,000. The complete terms of the warrants are attached as Schedule 8.1.g. Schedule 8.1.g constitutes an integrated part of these Articles of Association.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 5. maj 2015 vedtog Selskabets bestyrelse at udstede warrants (2015-4 employee incentive program) i henhold til bemyndigelse, som udløb den 2. november 2015, svarende til nominelt DKK 46.359 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed i henhold til bemyndigelse, som udløb den 2. november 2015. Det konkrete antal warrants tildelt udgør 46.359. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4. Bilag 8.4 udgør en integreret del af nærværende vedtægter.

 

At a meeting of the board of directors of the Company held on 5 May 2015, the board of directors of the Company resolved to issue warrants (2015-4 employee incentive program) pursuant to an authorization which expired on 2 November 2015, corresponding to a nominal amount of DKK 46,359 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith pursuant to an authorization which expired on 2 November 2015. The final number of warrants granted is 46,359. The complete terms of the warrants are attached as Schedule 8.4. Schedule 8.4 constitutes an integrated part of these Articles of Association.

 

 

 

8.2                 Alle aktier, der ved udnyttelse af warrants udstedt i henhold til § 8.1 skal være omsætningspapirer og navneaktier og noteres i Selskabets ejerbog.

 

The shares subscribed for by exercise of the warrants issued pursuant to article 8.1 shall be negotiable instruments and issued in the holder’s name and shall be registered in the Company’s Register of Shareholders.

 

 

 

De nye aktier skal være ligestillet med den bestående aktiekapital. Ingen aktionær skal være forpligtet til at lade sine aktier indløse helt eller delvist. De nye aktier skal give ret til udbytte og

 

The new shares shall have the same rights as the existing shares of the Company. No shareholder shall be obliged to have the shares redeemed fully or partly. The new shares shall

 


 

andre rettigheder i Selskabet fra det tidspunkt, som fastsættes af bestyrelsen i forhøjelsesbeslutningen.

 

give rights to dividends and other rights in the Company from the time which is determined by the board of directors in connection with the decision to increase the share capital.

 

 

 

8.3                 Bestyrelsen er bemyndiget til at ændre nærværende vedtægter i tilfælde af udnyttelse af de givne bemyndigelser eller warrants.

 

The board of directors is authorized to amend these Articles of Association as a consequence of applying the authorizations granted or the exercise of warrants.

 

 

 

8.4                 Bestyrelsen er i perioden indtil den 21. april 2020 bemyndiget til ad en eller flere gange at udstede warrants med ret til at tegne op til nominelt DKK 2.750.000 aktier i Selskabet. Selskabets aktionærer skal ikke have fortegningsret ved bestyrelsens udnyttelse af denne bemyndigelse. De nærmere vilkår fastsættes af bestyrelsen. Bestyrelsen fastsætter selv udnyttelseskursen samt øvrige vilkår for warrants, dog således at udnyttelseskursen som minimum skal svare til markedskursen på tidspunktet for udstedelsen af warrants, medmindre disse udstedes til Selskabets medarbejdere.

 

During the period until 21 April 2020 the board of directors is authorized to issue at one or more times warrants with a right to subscribe for shares up to an aggregate amount of nominally DKK 2,750,000 shares in the Company. The shareholders of the Company will not have pre-emptive subscription rights when the Board of Directors exercises this authorization. The specific terms and conditions in this respect are to be determined by the Board of Directors. The Board of Directors determines, at its own discretion, the exercise price as well as other terms and conditions for the warrants, always provided that the exercise price as a minimum corresponds to the market price at the time of issuance of the warrants, unless these are issued to the Company’s employees.

 

 

 

Bestyrelsen kan efter de til enhver tid gældende regler i selskabsloven genanvende eller genudstede eventuelle bortfaldne ikke udnyttede warrants, forudsat at genanvendelsen eller genudstedelsen finder sted inden for de vilkår og tidsmæssige begrænsninger, der fremgår af denne bemyndigelse. Ved genanvendelse forstås adgangen for bestyrelsen til at lade en anden aftalepart indtræde i en

 

Pursuant to the provisions of the Danish Companies Act in force from time to time, the Board of Directors may reapply or reissue any lapsed non-exercised warrants, provided that such reapplication or reissue is made under the terms and conditions and within the time limits specified under this authority. Reapplication means the right of the Board of Directors to let another contractual party become a

 


 

allerede bestående aftale om warrants. Ved genudstedelse forstås bestyrelsens mulighed for inden for samme bemyndigelse at genudstede nye warrants, hvis allerede udstedte warrants er bortfaldet.

 

party to an already existing agreement on warrants. Reissue means the possibility for the Board of Directors to reissue new warrants under the same authorization if those already issued have lapsed.

 

 

 

Bestyrelsen er i perioden indtil den 21. april 2020 endvidere bemyndiget til ad en eller flere gange at forhøje Selskabets aktiekapital med op til nominelt DKK 2.750.000 aktier ved kontant indbetaling i forbindelse med udnyttelse af warrants eller et sådant beløb som måtte følge af en eventuel regulering af antallet af warrants ved ændringer i Selskabets kapitalforhold. Selskabets aktionærer skal ikke have fortegningsret til aktier som udstedes ved udnyttelse af udstedte warrants.

 

During the period until 21 April 2020, the Board of Directors is also authorized to increase at one or more times the Company’s share capital by up to nominally DKK 2,750,000 shares by cash payment in connection with the exercise of the warrants or such an amount caused by an adjustment (if any) in the number of warrants due to changes in the capital structure, without pre-emptive subscription rights for the shareholders of the Company to shares issued by exercise of the issued warrants.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 5. maj 2015 vedtog Selskabets bestyrelse at udstede warrants (2015-2 employee incentive program) svarende til nominelt DKK 366.250 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 366.250. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4. Bilag 8.4 udgør en integreret del af nærværende vedtægter. 16.500 warrants udstedt under dette program er pr. 14. december 2018 bortfaldet. 7.500 warrants er udnyttet den 14. september 2018, og 18.250 warrants er udnyttet den 5. april 2019. Som følge af dels udnyttelse dels bortfald af warrants, er det udestående antal warrants, der kan udnyttes, reduceret til 324.000 warrants.

 

At a meeting of the board of directors of the Company held on 5 May 2015, the board of directors of the Company resolved to issue warrants (2015-2 employee incentive program) corresponding to a nominal amount of DKK 366,250 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 366,250. The complete terms of the warrants are attached as Schedule 8.4. Schedule 8.4 constitutes an integrated part of these Articles of Association. 16,500 warrants issued under this program has lapsed per 14 December 2018. 7,500 warrants were exercised on 14 September 2018, and 18,250 warrants were exercised on 5 April 2019. As a result of exercise/lapse of warrants, the number of warrants available for exercise has been reduced to 324,000 warrants.

 


 

På et bestyrelsesmøde i Selskabet afholdt den 5. maj 2015 vedtog Selskabets bestyrelse at udstede warrants (2015-3 employee incentive program) svarende til nominelt DKK 100.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.a.

 

At a meeting of the board of directors of the Company held on 5 May 2015, the board of directors of the Company resolved to issue warrants (2015-3 employee incentive program) corresponding to a nominal amount of DKK 85,434 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.a is terminated.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 5. april 2016 vedtog Selskabets bestyrelse at udstede warrants (2016-1 employee incentive program) svarende til nominelt DKK 347.250 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 347.250. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.b. Bilag 8.4.b udgør en integreret del af nærværende vedtægter. 25.500 warrants udstedt under dette program er pr. 14. december 2018 bortfaldet. Som følge af bortfald af warrants, er det udestående antal warrants, der kan udnyttes, reduceret til 321.750 warrants.

 

At a meeting of the board of directors of the Company held on 5 April 2016, the board of directors of the Company resolved to issue warrants (2016-1 employee incentive program) corresponding to a nominal amount of DKK 347,250 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 347,250. The complete terms of the warrants are attached as Schedule 8.4.b. Schedule 8.4.b constitutes an integrated part of these Articles of Association. 25,500 warrants issued under this program has lapsed per 14 December 2018. As a result of lapse of warrants, the number of warrants available for exercise has been reduced to 321,750 warrants.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 5. april 2016 vedtog Selskabets bestyrelse at udstede warrants (2016-2 employee incentive program) svarende til nominelt DKK 85.434 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets

 

At a meeting of the board of directors of the Company held on 5 April 2016, the board of directors of the Company resolved to issue warrants (2016-2 employee incentive program) corresponding to a nominal amount of DKK 85,434 shares; and the board of directors at the same time resolved to

 


 

aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.c.

 

increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.c is terminated.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 15. juli 2016 vedtog Selskabets bestyrelse at udstede warrants (2016-3 employee incentive program) svarende til nominelt DKK 40.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 40.000. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.d. Bilag 8.4.d udgør en integreret del af nærværende vedtægter.

 

At a meeting of the board of directors of the Company held on 15 July 2016, the board of directors of the Company resolved to issue warrants (2016-3 employee incentive program) corresponding to a nominal amount of DKK 40,000 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 40,000. The complete terms of the warrants are attached as Schedule 8.4.d. Schedule 8.4.d constitutes an integrated part of these Articles of Association.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 6. april 2017 vedtog Selskabets bestyrelse at udstede warrants (2017-1 employee incentive program) svarende til nominelt DKK 424.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 424.000. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.e. Bilag 8.4.e udgør en integreret del af nærværende vedtægter. 43.000 warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants, er det udestående antal warrants, der kan udnyttes, reduceret til 381.000 warrants.

 

At a meeting of the board of directors of the Company held on 6 April 2017, the board of directors of the Company resolved to issue warrants (2017-1 employee incentive program) corresponding to a nominal amount of DKK 424,000 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 424,000. The complete terms of the warrants are attached as Schedule 8.4.e. Schedule 8.4.e constitutes an integrated part of these Articles of Association. 43,000 warrants issued under this program has lapsed per 28 February 2019. As a result of lapse of warrants, the number of warrants available for exercise has been reduced to 381,000 warrants.

 


 

På et bestyrelsesmøde i Selskabet afholdt den 6. april 2017 vedtog Selskabets bestyrelse at udstede warrants (2017-2 employee incentive program) svarende til nominelt DKK 93.392 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.f.

 

At a meeting of the board of directors of the Company held on 6 April 2017, the board of directors of the Company resolved to issue warrants (2017-2 employee incentive program) corresponding to a nominal amount of DKK 93,392 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.f is terminated.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 25. august 2017 vedtog Selskabets bestyrelse at udstede warrants (2017-3 employee incentive program) svarende til nominelt DKK 14.566 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.g.

 

At a meeting of the board of directors of the Company held on 25 August 2017, the board of directors of the Company resolved to issue warrants (2017-3 employee incentive program) corresponding to a nominal amount of DKK 14,566 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.g is terminated.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 25. august 2017 vedtog Selskabets bestyrelse at udstede warrants (2017-4 employee incentive program) svarende til nominelt DKK 6.608 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.h.

 

At a meeting of the board of directors of the Company held on 25 August 2017, the board of directors of the Company resolved to issue warrants (2017-4 employee incentive program) corresponding to a nominal amount of DKK 6,608 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.h is terminated.

 


 

På et bestyrelsesmøde i Selskabet afholdt den 22. maj 2018 vedtog Selskabets bestyrelse at udstede warrants (2018-1 employee incentive program) svarende til nominelt DKK 515.500 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 515.500. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.i. Bilag 8.4.i udgør en integreret del af nærværende vedtægter. 5.500 warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants, er det udestående antal warrants, der kan udnyttes, reduceret til 510.000 warrants.

 

At a meeting of the board of directors of the Company held on 22 May 2018, the board of directors of the Company resolved to issue warrants (2018-1 employee incentive program) corresponding to a nominal amount of DKK 515,500 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 515,500. The complete terms of the warrants are attached as Schedule 8.4.i. Schedule 8.4.i constitutes an integrated part of these Articles of Association. 5,500 warrants issued under this program has lapsed per 28 February 2019. As a result of lapse of warrants, the number of warrants available for exercise has been reduced to 510,000 warrants.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 22. maj 2018 vedtog Selskabets bestyrelse at udstede warrants (2018-1 employee incentive program) svarende til nominelt DKK 100.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Samtlige warrants udstedt under dette program er pr. 28. februar 2019 bortfaldet. Som følge af bortfald af warrants ophæves bilag 8.4.j.

 

At a meeting of the board of directors of the Company held on 22 May 2018, the board of directors of the Company resolved to issue warrants (2018-1 employee incentive program) corresponding to a nominal amount of DKK 100,000 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. All warrants issued under this program have lapsed per 28 February 2019. As a result of lapse of warrants, Schedule 8.4.j is terminated.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 15. oktober 2018 vedtog Selskabets bestyrelse at udstede warrants (2018-2 employee incentive program) svarende til nominelt DKK 40.000 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse

 

At a meeting of the board of directors of the Company held on 15 October 2018, the board of directors of the Company resolved to issue warrants (2018-2 employee incentive program) corresponding to a nominal amount of DKK 40,000 shares; and the board of directors at the same time resolved to increase the share capital of the

 


 

dermed. Det konkrete antal warrants tildelt udgør 40.000. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.k. Bilag 8.4.k udgør en integreret del af nærværende vedtægter.

 

Company in accordance therewith. The final number of warrants granted is 40,000. The complete terms of the warrants are attached as Schedule 8.4.k. Schedule 8.4.k constitutes an integrated part of these Articles of Association.

 

 

 

På et bestyrelsesmøde i Selskabet afholdt den 10. april 2019 vedtog Selskabets bestyrelse at udstede warrants (2019-1 employee incentive program) svarende til nominelt DKK 397.750 aktier; og bestyrelsen vedtog samtidig at forhøje Selskabets aktiekapital i overensstemmelse dermed. Det konkrete antal warrants tildelt udgør 397.750. De fuldstændige vilkår for warrants er vedlagt som bilag 8.4.l. Bilag 8.4.l udgør en integreret del af nærværende vedtægter.

 

At a meeting of the board of directors of the Company held on 10 April 2019, the board of directors of the Company resolved to issue warrants (2019-1 employee incentive program) corresponding to a nominal amount of DKK 397,750 shares; and the board of directors at the same time resolved to increase the share capital of the Company in accordance therewith. The final number of warrants granted is 397,750. The complete terms of the warrants are attached as Schedule 8.4.l. Schedule 8.4.l constitutes an integrated part of these Articles of Association.

 

 

 

Som følge af dels udstedelse af warrants dels bortfald af warrants, er det udestående antal warrants, der kan udstedes i henhold til bemyndigelsen i nærværende § 8.4, ændret til 709.750 warrants.

 

As a result of issuance/lapse of warrants, the number of warrants available for issuance under the authorization in this article 8.4 has been changed to 709,750 warrants.

 

 

 

8.5                 Alle aktier, der tegnes ved udnyttelse af warrants udstedt i henhold til § 8.4, skal være omsætningspapirer og navneaktier og noteres i Selskabets ejerbog.

 

The shares subscribed for by exercise of the warrants issued pursuant to article 8.4 shall be negotiable instruments and issued in the holder’s name and shall be registered in the Company’s Register of Shareholders.

 

 

 

De nye aktier skal være ligestillet med den bestående aktiekapital. Ingen aktionær skal være forpligtet til at lade sine aktier indløse helt eller delvist. De nye aktier skal give ret til udbytte og andre rettigheder i Selskabet fra det

 

The new shares shall have the same rights as the existing shares of the Company. No shareholder shall be obliged to have the shares redeemed fully or partly. The new shares shall give rights to dividends and other rights in the Company from the time

 


 

tidspunkt, som fastsættes af bestyrelsen i forhøjelsesbeslutningen.

 

which is determined by the Board of Directors in connection with the decision to increase the share capital.

 

 

 

8.6                 Bestyrelsen er bemyndiget til at ændre nærværende vedtægter i tilfælde af udnyttelse af de givne bemyndigelser eller warrants.

 

The board of directors is authorized to amend these Articles of Association as a consequence of applying the authorizations granted or the exercise of warrants.

 

 

 

9                           Generalforsamling

 

General Meetings

 

 

 

9.1                 Generalforsamlinger afholdes i Storkøbenhavn.

 

General meetings of the Company shall be held in Greater Copenhagen.

 

 

 

9.2                 Ordinære generalforsamlinger skal afholdes i så god tid, at den reviderede og godkendte årsrapport kan indsendes og være modtaget i Erhvervsstyrelsen senest fire måneder efter regnskabsårets udløb.

 

Annual general meetings shall be held early enough for the audited and adopted annual report to be submitted to and received by the Danish Business Authority not later than four months after the closing of the financial year.

 

 

 

9.3                 Bestyrelsen skal senest otte uger før dagen for den påtænkte afholdelse af den ordinære generalforsamling offentliggøre datoen for afholdelsen af generalforsamlingen samt datoen for den seneste fremsættelse af krav om optagelse af et bestemt emne på dagsordenen for aktionærerne, jf. punkt 9.4.

 

Not later than eight weeks before the date set for the annual general meeting the board of directors shall announce the date on which it intends to hold the general meeting as well as the date by which requests filed by shareholders wishing to have specific items included on the agenda, cf. article 9.4.

 

 

 

9.4                 Forslag fra aktionærerne til behandling på den ordinære generalforsamling skal være skriftligt fremsat til bestyrelsen senest seks uger før generalforsamlingens afholdelse. Modtager bestyrelsen et forslag senere end seks uger før generalforsamlingens afholdelse, afgør bestyrelsen, om forslaget er fremsat i så god tid, at emnet alligevel kan optages på dagsordenen.

 

Proposals from shareholders for consideration by the annual general meeting shall be submitted to the board of directors in writing not later than six weeks before the date of the general meeting. In the event that the board of directors receives a proposal later than six weeks before the general meeting, the board of directors shall decide whether it was received in time for it to be included on the agenda nonetheless.

 


 

9.5                 Ekstraordinær generalforsamling afholdes efter en generalforsamlings beslutning, bestyrelsens beslutning, når det kræves af Selskabets revisor, eller når det til behandling af et bestemt emne skriftligt kræves af aktionærer, der ejer mindst 5 % af aktiekapitalen.

 

An extraordinary general meeting shall be held when decided by a general meeting, the board of directors or requested by the Company’s auditor as well as when requested in writing by shareholders holding at least 5% of the share capital for consideration of a specific issue.

 

 

 

9.6                 Alle dokumenter til brug for Selskabets generalforsamlinger i forbindelse med eller efter generalforsamlingen, herunder indkaldelsen og forhandlingsprotokollen, skal alene udarbejdes på engelsk.

 

All documents prepared for use by or for a general meeting of the Company in connection with or after the general meeting, including the notice and the minutes, must be prepared in English only.

 

 

 

9.7                 Generalforsamlinger skal indkaldes med højst fem ugers og mindst tre ugers varsel. Indkaldelse til ekstraordinær generalforsamling skal ske senest 14 dage efter, at bestyrelsen har modtaget behørig anmodning herom.

 

General meetings shall be convened with a maximum notice of five weeks and a minimum notice of three weeks. An extraordinary general meeting shall be convened within 14 days after a proper request has been received by the board of directors.

 

 

 

9.8                 Bestyrelsen skal indkalde til generalforsamling ved bekendtgørelse indrykket i Erhvervsstyrelsens it-system samt ved offentliggørelse på Selskabets hjemmeside (www.zealandpharma.com).

 

The board of directors shall convene general meetings by publication in the computer information system of the Danish Business Authority and by posting on the Company’s website
(www.zealandpharma.com).

 

 

 

9.9                 Indkaldelsesvarslet regnes fra den første bekendtgørelse. Indkaldelse sker endvidere ved meddelelse til alle noterede aktionærer i ejerbogen, som har fremsat begæring herom, til den adresse, herunder e-mailadresse, jf. punkt 12, de har opgivet til Selskabet. Er oplysningerne i ejerbogen utilstrækkelige eller mangelfulde, har bestyrelsen ingen pligt til at søge disse berigtiget eller til at indkalde på anden måde.

 

The length of the notice shall be reckoned from the first advertisement. General meetings shall moreover be convened by sending a notice to all shareholders entered in the Company’s Register of Shareholders having so requested, to the address, including the e-mail address, cf. article 12, informed to the Company. If the information contained in the Register of Shareholders is insufficient or incorrect, the board of directors shall not be obliged to rectify the

 


 

 

 

information or to give notice in any other way.

 

 

 

9.10          Indkaldelsen skal som minimum indeholde:

 

The notice shall as a minimum include:

 

 

 

(1)         Tid og sted for generalforsamlingen, samt hvilke emner der skal behandles på generalforsamlingen. Såfremt der på generalforsamlingen skal behandles forslag til vedtægtsændringer, skal forslagets væsentligste indhold angives i indkaldelsen.

 

(1)         Time and place for the general meeting and the issues to be considered at the general meeting. If the general meeting is to consider a proposal to amend the Articles of Association, then the notice shall specify the material content of the proposal.

 

 

 

(2)         En beskrivelse af aktiekapitalens størrelse og aktionærernes stemmeret.

 

(2)         The amount of the share capital and the voting rights of the shareholders.

 

 

 

(3)         Den i vedtægternes punkt 10.2 nævnte registreringsdato med en tydeliggørelse af, at det alene er selskaber eller personer, der på denne dato er aktionærer i Selskabet, der har ret til at deltage i og stemme på generalforsamlingen.

 

(3)         The registration date stated in article 10.2 with a clear indication that only companies or persons holding shares in the Company as at said date shall be entitled to attend and vote at the general meeting.

 

 

 

(4)         Angivelse af hvor og hvordan den komplette, uforkortede tekst til de dokumenter, der skal fremlægges på generalforsamlingen, dagsordenen og de fuldstændige forslag kan fås, herunder den nøjagtige internetadresse til Selskabets hjemmeside, hvor dagsordenen og de dokumenter nævnt i punkt 12.2 vil blive gjort tilgængelige.

 

(4)         An indication of where and how to obtain the full, unbridged text of the documents to be presented at the general meeting, the agenda and the complete proposals, including the exact internet address of the Company’s website where the agenda and the other documents mentioned in article 12.2 will be made available.

 

 

 

(5)         Proceduren for stemmeafgivelse ved fuldmagt, brev og ved elektronisk stemmeafgivelse, herunder at der vil blive stillet en fuldmagtsblanket til rådighed for

 

(5)         The procedure for voting by proxy, by postal and by electronic means, and the Company will make a proxy form available for the

 


 

enhver stemmeberettiget aktionær.

 

shareholders that are entitled to vote.

 

 

 

(6)         Såfremt generalforsamlingen gennemføres elektronisk eller delvis elektronisk, jf. punkt 11.1, skal indkaldelsen tillige indeholde oplysninger derom samt om tilmelding og de nærmere krav til de elektroniske systemer som vil blive anvendt. Indkaldelsen skal angive, at oplysninger om fremgangsmåden ved elektronisk generalforsamling vil kunne findes på Selskabets hjemmeside.

 

(6)         If the general meeting is conducted by electronic means or partly by electronic means, cf. article 11.1 this shall be stated in the convening notice together with the details on how to sign up and what the requirements are to the electronic systems that will be used. The convening notice shall point out that detailed information about the procedure will be available on the Company’s website.

 

 

 

9.11          Generalforsamlingen afholdes på engelsk, uden at der sker simultantolkning til dansk.

 

The general meeting is held in English without simultaneous translation to Danish.

 

 

 

9.12          Senest tre uger før generalforsamlingen skal følgende oplysninger som minimum være tilgængelige på Selskabets hjemmeside:

 

Not later than three weeks prior to a general meeting the following information, as minimum, shall be available on the Company’s website:

 

 

 

(1)         Indkaldelsen.

 

(1)         The notice.

 

 

 

(2)         Det samlede antal aktier og stemmerettigheder på datoen for indkaldelsen.

 

(2)         The total number of shares and voting rights on the date of the notice.

 

 

 

(3)         De dokumenter, der skal fremlægges på generalforsamlingen, herunder for den ordinære generalforsamlings vedkommende den reviderede årsrapport.

 

(3)         The documents to be submitted to the general meeting, including with respect to the annual general meeting the audited annual report.

 

 

 

(4)         Dagsordenen og de fuldstændige forslag.

 

(4)         The agenda and complete proposals.

 

 

 

(5)         De formularer, der skal anvendes ved stemmeafgivelse ved fuldmagt og ved brev.

 

(5)         The forms to be used for voting by proxy or postal.

 


 

9.13          Dagsordenen for den ordinære generalforsamling skal omfatte:

 

The agenda of the annual meeting shall include:

 

 

 

(1)         Bestyrelsens beretning om Selskabets virksomhed i det forløbne regnskabsår.

 

(1)         A report from the board of directors on the Company’s activities in the past financial year.

 

 

 

(2)         Godkendelse af den reviderede årsrapport.

 

(2)         Approval of the audited annual report.

 

 

 

(3)         Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport.

 

(3)         A resolution on the distribution of profit or the cover of loss in accordance with the annual report adopted.

 

 

 

(4)         Valg af medlemmer til bestyrelsen.

 

(4)         Election of members to the board of directors.

 

 

 

(5)         Valg af revisor.

 

(5)         Election of auditor.

 

 

 

(6)         Bemyndigelse til erhvervelse af egne aktier.

 

(6)         Authorization to acquire the Company’s own shares.

 

 

 

(7)         Eventuelle forslag fra bestyrelse eller aktionærer.

 

(7)         Any proposals submitted by the board of directors or by shareholders.

 

 

 

(8)         Eventuelt.

 

(8)         Any other business.

 

 

 

9.14          Forhandlingerne på generalforsamlingen ledes af en dirigent, der udpeges af bestyrelsen. Dirigenten afgør alle spørgsmål vedrørende emnernes behandling, stemmeafgivning og stemmeresultaterne.

 

A chairman of the meeting appointed by the board of directors shall preside over the proceedings at general meetings and decide upon all questions of procedure, voting and voting results.

 

 

 

9.15          Et referat af generalforsamlingen indføres i en protokol. Referatet skal underskrives af dirigenten og af bestyrelsens formand. Senest to uger efter generalforsamlingens afholdelse skal generalforsamlingsprotokollen eller en bekræftet udgave af denne gøres tilgængelig for Selskabets aktionærer.

 

The proceedings at a general meeting shall be recorded in a minute book and be signed by the chairman of the general meeting and the chairman of the board of directors. Not later than two weeks after the general meeting the minute book, or a certified transcript of the minute book, shall be made available to the Company’s

 


 

 

 

shareholders.

 

 

 

9.16          Generalforsamlingsprotokollen skal for hver beslutning som udgangspunkt indeholde en fuldstændig redegørelse for afstemningen, derunder om (i) hvor mange aktier, der er afgivet gyldige stemmer for, (ii) den andel af aktiekapitalen, som disse stemmer repræsenterer, (iii) det samlede antal gyldige stemmer, (iv) det samlede antal af stemmer for og imod hvert beslutningsforslag og (v) antallet af eventuelle stemmeundladelser.

 

As a general rule, for each resolution made at the general meeting the minute book of the general meeting must set out at a minimum the full details of the voting including information on (i) the total number of shares for which valid votes were cast, (ii) the proportion of the share capital accounted for by these votes, (iii) the total number of valid votes, (iv) the number of votes cast in favour of and against each resolution, and (v) the total number of abstentions, if any.

 

 

 

9.17          Ønsker ingen af aktionærerne en fuldstændig redegørelse for afstemningerne, er det kun nødvendigt i generalforsamlingsprotokollen at fastslå afstemningsresultatet for hver beslutning. Dirigenten skal således i forbindelse med hver generalforsamlingsbeslutning have afklaret hvorvidt, ingen af aktionærerne ønsker en fuldstændig redegørelse for afstemningen.

 

If no shareholder requests that the full details of the votes be included in the minute book, the minute book need only to state the results of the individual votes. Accordingly, the Chairman of the general meeting shall have to clarify for each individual vote whether or not any shareholders request the inclusion in the minute book of the full details of the vote.

 

 

 

9.18          Senest to uger efter generalforsamlingens afholdelse skal afstemningsresultatet offentliggøres på Selskabets hjemmeside.

 

Not later than two weeks after the general meeting the voting results from the general meeting shall be posted on the Company’s website.

 

 

 

10                    Møderet - Stemmeret

 

Right of Attendance - Voting Right

 

 

 

10.1          En aktionærs ret til at deltage i og afgive stemme på en generalforsamling fastsættes i forhold til de aktier, som aktionæren besidder på registreringsdatoen.

 

A shareholders right to attend general meetings and to vote at general meetings is determined on the basis of the shares that the shareholder owns on the registration date.

 

 

 

10.2          Registreringsdatoen ligger en uge før generalforsamlingens afholdelse. De aktier, den enkelte aktionær besidder, opgøres på registreringsdatoen på grundlag af noteringen af aktionærens

 

The registration date is one week before the general meeting is held. The shares which the individual shareholder owns are calculated on the registration date on the basis of the

 


 

ejerforhold i ejerbogen samt meddelelser om ejerforhold, som Selskabet har modtaget med henblik på indførsel i ejerbogen.

 

registration of ownership in the Company’s Register of Shareholders as well as notifications concerning ownership which the Company has received with a view to update the ownership in the Register of Shareholders.

 

 

 

10.3          Enhver aktionær som senest tre dage inden generalforsamlingens afholdelse har meddelt Selskabet sin deltagelse, og som har modtaget et adgangskort, er berettiget til personligt eller ved fuldmagt at deltage i generalforsamlingen. Adgangskort udstedes til den i Selskabets ejerbog noterede aktionær.

 

Any shareholder who has notified the Company of his participation not later than three days prior to the general meeting and who has received an admission card shall be entitled to attend the general meeting, either in person or by proxy. Admission card will be issued to the holder registered in the Company’s Register of Shareholders.

 

 

 

10.4          På generalforsamlingen giver hvert aktiebeløb på DKK 1 én stemme. En aktionær har ret til at udøve stemmerettighederne i tilknytning til nogle af sine aktier på en måde, der ikke er identisk med udøvelsen af stemmerettighederne i tilknytning til andre af dennes aktier.

 

Each share of DKK 1 has one vote at general meetings. A shareholder may exercise the voting rights attached to some of his/her shares in a manner that is not identical to the exercise of the voting rights attached to his/her other shares.

 

 

 

10.5          Stemmeret kan udøves i henhold til skriftlig fuldmagt eller ved brevstemme, og Selskabet skal senest tre uger før generalforsamlingen gøre formularer til brug herfor tilgængelige på Selskabets hjemmeside. En brevstemme skal være Selskabet i hænde senest tre dage før generalforsamlingens afholdelse for at blive medtaget på generalforsamlingen.

 

A shareholder may vote by proxy or by postal, and the Company shall not later than three weeks prior to the general meeting make a form for this use available on the Company’s website. A vote by postal must be received by the Company not later than three days prior to the general meeting is held in order to be counted at the general meeting.

 

 

 

10.6          Aktionæren eller fuldmægtigen kan møde på generalforsamlingen sammen med en rådgiver.

 

The shareholder or the proxyholder may attend the general meeting accompanied by an advisor.

 

 

 

10.7          Generalforsamlingen træffer beslutning ved simpelt stemmeflertal,

 

At general meetings resolutions shall be decided by simple majority of votes

 


 

medmindre andet følger af lovgivningen eller af Selskabets vedtægter.

 

unless otherwise prescribed by law or the Articles of Association.

 

 

 

11                    Elektronisk generalforsamling

 

Electronic general meetings

 

 

 

11.1          Bestyrelsen kan, når den anser det for hensigtsmæssigt og generalforsamlingen kan afvikles på betryggende vis, bestemme at generalforsamlingen udelukkende skal foregå elektronisk (fuldstændig elektronisk generalforsamling). Bestyrelsen kan herudover under samme forudsætninger vælge at tilbyde aktionærerne at deltage elektronisk på generalforsamlinger, der i øvrigt gennemføres ved fysisk fremmøde (delvis elektronisk generalforsamling). Aktionærerne kan derved elektronisk deltage i, ytre sig samt stemme på generalforsamlingen. Nærmere oplysninger vil til sin tid kunne findes på Selskabets hjemmeside og i indkaldelsen til de pågældende generalforsamlinger, ligesom de i Selskabets ejerbog noterede aktionærer vil modtage skriftlig meddelelse herom.

 

When the board of directors finds it appropriate and technically safe it may decide that the general meeting solely shall be held as an electronic general meeting (completely electronic general meeting). The board of directors may also as an alternative under the same circumstances invite shareholders to attend by electronic means general meetings that are also attended by shareholders in person (partially electronic general meeting). In this way, shareholders will be able to attend, express their opinion and vote at the general meeting by electronic means. In due course more information will be made available on the Company’s website and in the notices convening the general meetings involved, and written information on the subject will also be sent to shareholders listed in the Company’s Register of Shareholders.

 

 

 

12                    Elektronisk kommunikation

 

Electronic communication

 

 

 

12.1          Bestyrelsen er bemyndiget til at indføre elektronisk kommunikation mellem Selskabet og dets aktionærer, således at Selskabet kan benytte elektronisk dokumentudveksling og elektronisk post, som nærmere angivet nedenfor i sin kommunikation med aktionærerne.

 

The board of directors has been granted authority to introduce electronic communication between the Company and its shareholders, meaning that the Company may use electronic document exchange and electronic mail as specified below in its communication with the shareholders.

 

 

 

12.2          Indkaldelse af aktionærerne til ordinær og ekstraordinær generalforsamling, herunder de fuldstændige forslag til vedtægtsændringer, tilsendelse af dagsorden, årsrapport, delårsrapport,

 

The Company shall be able to send notices convening annual and extraordinary general meetings including the complete proposals for amendments to the articles of

 


 

kvartalsrapport, fondsbørsmeddelelser, generalforsamlingsprotokollater, fuldmagtsblanketter og adgangskort samt øvrige generelle oplysninger fra Selskabet til aktionærerne vil kunne sendes af Selskabet til aktionærerne via e-mail.

 

association, agenda, annual report, interim report, quarterly report, stock exchange releases, minutes and general meetings, proxy forms, mail-in voting forms, admission cards and other general information from the Company to it shareholders by means of email.

 

 

 

12.3          Ovennævnte dokumenter, bortset fra adgangskort til generalforsamlingen, vil tillige blive offentliggjort på Selskabets hjemmeside. På Selskabets hjemmeside vil der tillige kunne findes oplysning om kravene til de anvendte systemer samt om fremgangsmåden i forbindelse med elektronisk kommunikation.

 

The above documents, to the exclusion of admission cards for the general meeting, shall also be posted on the Company’s website. The Company’s website shall also contain information about requirements to the systems used and the procedures applying to the use of electronic communication.

 

 

 

12.4          Selskabet er forpligtet til at bede navnenoterede aktionærer om en elektronisk adresse hvortil meddelelser m.v. kan sendes, og det er den enkelte aktionærs ansvar at sikre, at Selskabet er i besiddelse af den korrekte elektroniske adresse.

 

The Company must request registered shareholders for an electronic address to which notices can be sent, and it is the responsibility of each shareholder to ensure that the Company is in possession of a proper electronic address.

 

 

 

13                    Bestyrelse

 

Board of Directors

 

 

 

13.1          Til Selskabets bestyrelse vælger generalforsamlingen mindst fire og højst syv medlemmer.

 

The general meeting shall elect at least four and not more than seven directors.

 

 

 

13.2          Bestyrelsesmedlemmer, som er valgt af generalforsamlingen, afgår på hvert års ordinære generalforsamling, men kan genvælges.

 

The directors elected by the general meeting shall retire from office at each annual general meeting but shall be eligible for re-election.

 

 

 

13.3          Bestyrelsen vælger af sin midte en formand og en næstformand.

 

The board of directors elects a chairman and a vice-chairman from among its members.

 


 

13.4          Beslutninger i bestyrelsen træffes, medmindre andet er aftalt, med almindelig stemmeflerhed. I tilfælde af stemmelighed er formandens, og i hans/hendes forfald næstformandens, stemme udslagsgivende.

 

Unless otherwise decided by the board of directors, decisions of the board of directors shall be decided by simple majority of votes. In the event of an equality of votes, the chairman, and in his/her absence the vice-chairman, shall have a casting vote.

 

 

 

13.5          Bestyrelsen træffer ved en forretningsorden nærmere bestemmelse om udførelsen af sit hverv.

 

The board of directors shall lay down rules of its proceedings.

 

 

 

13.6          Bestyrelsesmedlemmerne oppebærer et årligt honorar, hvis samlede størrelse skal fremgå af årsrapporten for det pågældende år.

 

The directors shall be remunerated annually as prescribed in the annual report for the relevant year.

 

 

 

13.7          Bestyrelsen kan meddele prokura, enkel eller kollektiv.

 

The board of directors may authorize one person alone or more persons jointly to sign for the Company by procuration.

 

 

 

14                    Direktion

 

Executive management

 

 

 

14.1          Bestyrelsen ansætter en direktion bestående af mellem en og fire direktører. Hvis direktionen består af flere direktører, skal én af disse udnævnes til administrerende direktør.

 

The board of directors shall employ at least one but not more than four managers to comprise the Company’s executive management. Where more than one manager is employed, one of them shall be appointed managing director.

 

 

 

14.2          Bestyrelsen er bemyndiget til at beslutte at lade Selskabet skadesløsholde medlemmerne af direktionen samt Selskabets medarbejdere for visse krav, der er knyttet til deres rolle i Selskabet.

 

The board of directors is authorized to resolve to let the Company indemnify the members of executive management and the Company’s employees for certain claims against these individuals in connection with their services to the Company.

 

 

 

Selskabets skadesløsholdelse omfatter krav og rimelige sagsomkostninger, der er knyttet til den planlagte notering af selskabet i USA og/eller Selskabets efterfølgende status som noteret i USA.

 

The Company’s indemnification covers claims and reasonable legal costs arising from the listing of the Company in the United States and/or the Company’s subsequent status as listed

 


 

 

 

in the United States.

 

 

 

Selskabets skadesløsholdelse skal ikke omfatte følgende krav:

 

However, the Company’s indemnification shall not cover the following claims:

 

 

 

1)             Krav mod en person, der gøres gældende efter dansk ret ved en dansk domstol, medmindre der er tale om krav, der er knyttet til noteringen af Selskabet i USA og/eller Selskabets efterfølgende status som noteret i USA,

 

1)             Claims against a person according to Danish law raised before the Danish Courts, except claims arising from the listing of the Company in the United States and/or the Company’s subsequent status as listed in the United States,

 

 

 

2)             krav mod en person som følge af skader med tilhørende sagsomkostninger, der skyldes kriminelle handlinger og/eller grov uagtsomhed eller forsætlige handlinger eller undladelser, der er begået af personen,

 

2)             claims against a person for damages and legal costs related to criminal and/or grossly negligent or willful acts or omissions committed by the person,

 

 

 

3)             krav mod en person, som skyldes opnåelse eller forsøg på at opnå en gevinst eller anden type fordel, som personen eller en nærtstående fysisk eller juridisk person til personen ikke er berettiget til at opnå, og/eller

 

3)             claims against a person, which is attributable to the gaining or purported gaining of any profit or advantage to which the individual or any related natural or legal person was not legally entitled, and/or

 

 

 

4)             krav omfattet af forsikringsdækning. Hvis forsikringsselskabet nægter at dække krav af andre årsager end dem, der er nævnt oven for under pkt. 1 og 2, vil Selskabets skadesløsholdelse dække sådanne krav under forudsætning af, at Selskabet i sådanne tilfælde er berettiget til på ethvert tidspunkt at repræsentere den forsikrede

 

4)             claims covered by insurance. If the insurance company refuses to provide cover for reasons other than those mentioned in items 1 and 2 above, the Company’s indemnification will cover such claims, provided, however that the Company in such event shall be entitled at any time to represent the insured in respect of the insurance company and shall automatically by subrogation enter

 


 

under hensyntagen til forsikringsselskabet, og Selskabet skal automatisk overtage samtlige rettigheder i henhold til forsikringspolicen.

 

into any and all rights under said insurance policy.

 

 

 

Selskabets skadesløsholdelse pr. krav pr. person er begrænset til maksimalt det bruttoprovenu, Selskabet opnår i forbindelse med noteringen i USA.

 

The indemnification shall be limited to a maximum amount per claim per person equivalent to the gross proceeds obtained by the Company in connection with the listing in the United States.

 

 

 

Skadesløsholdelsen skal opretholdes i 5 år efter, at den skadesløsholdte person er fratrådt sin stilling hos Selskabet, hvis de krav, der rejses inden for denne periode, er knyttet til personens tidligere hverv i Selskabet.

 

The indemnification shall remain in force for a period of five years after the resignation of the indemnified person from such person’s position with the Company, if the claims made within such period are related to such person’s services to the Company.

 

 

 

15                    Incitamentsaflønning

 

Incentive Pay

 

 

 

15.1          Selskabet har udarbejdet overordnede retningslinjer for incitamentsaflønning af bestyrelsen og direktionen. Disse retningslinjer er forelagt og vedtaget af Selskabets generalforsamling. Retningslinjerne er offentligt tilgængelige på Selskabets hjemmeside.

 

The Company has prepared a set of general guidelines for incentive pay to the board of directors and the executive management. These guidelines have been presented to and adopted by the Company in general meeting. The guidelines are publicly available on the Company’s website.

 

 

 

16                    Tegningsregel

 

Signature Rules

 

 

 

16.1          Selskabet tegnes af bestyrelsens formand i forening med den administrerende direktør, eller af bestyrelsens formand i forening med et bestyrelsesmedlem, eller af en direktør i forening med to bestyrelsesmedlemmer, eller af den administrerende direktør i forening med en direktør eller af den samlede bestyrelse.

 

The Company shall be bound by the joint signatures of the chairman of the board of directors with the managing director; or the chairman of the board of directors jointly with one member of the board of directors; or one member of the board of managers jointly with two members of the board of directors; or the joint signatures of the managing director and one member of the board of managers; or all members of the board of directors jointly.

 


 

17                    Revisor

 

Auditor

 

 

 

17.1          Selskabets årsrapport revideres af en statsautoriseret revisor.

 

The Company’s annual report shall be audited by a state-authorized public accountant.

 

 

 

17.2          Revisor vælges af den ordinære generalforsamling for et år ad gangen.

 

The auditor shall be elected by the annual general meeting for one year at a time.

 

 

 

18                    Årsrapport

 

Annual Report

 

 

 

18.1          Selskabets regnskabsår er kalenderåret.

 

The financial year of the Company is the calendar year.

 

 

 

18.2          Selskabets årsrapport udarbejdes og aflægges udelukkende på engelsk.

 

The Company’s annual report shall be prepared and submitted in English only.

 

 

 

19                    Selskabsmeddelelser

 

Company Announcements

 

 

 

19.1          Selskabets offentliggørelse af information i henhold til gældende børslovgivning, herunder selskabsmeddelelser, sker udelukkende på engelsk.

 

The Company’s disclosure of information pursuant to applicable securities legislation, including company announcements, shall be in English only.

 

 

 

20                    Bilag

 

Schedules

 

 

 

20.1          Bilag 8.1.a: Warrants (2011-1 employee incentive program), jf. vedtægternes § 8.1.

 

Schedule 8.1.a: Warrants (2011-1 employee incentive program), cf. Article 8.1 of the Articles of Association.

 

 

 

20.2          Bilag 8.1.c: Warrants (2012-1 employee incentive program), jf. vedtægternes § 8.1.

 

Schedule 8.1.c: Warrants (2012-1 employee incentive program), cf. Article 8.1 of the Articles of Association.

 

 

 

20.3          Bilag 8.1.f: Warrants (2014-1 employee incentive program), jf. vedtægternes § 8.1.

 

Schedule 8.1.f: Warrants (2014-1 employee incentive program), cf. Article 8.1 of the Articles of Association.

 

 

 

20.4          Bilag 8.1.g: Warrants (2015-1 employee incentive program), jf. vedtægternes § 8.1.

 

Schedule 8.1.g: Warrants (2015-1 employee incentive program), cf. Article 8.1 of the Articles of Association.

 


 

20.5          Bilag 8.4: Warrants (2015-2 og 2015-4 employee incentive program), jf. vedtægternes § 8.1. og 8.4.

 

Schedule 8.4.: Warrants (2015-2 and 2015-4 employee incentive program), cf. Article 8.1 and 8.4 of the Articles of Association.

 

 

 

20.6          Bilag 8.4.b: Warrants (2016-1 employee incentive program), jf. vedtægternes § 8.4.

 

Schedule 8.4.b: Warrants (2016-1 employee incentive program), cf. Article 8.4 of the Articles of Association.

 

 

 

20.7          Bilag 8.4.d: Warrants (2016-3 employee incentive program), jf. vedtægternes § 8.4.

 

Schedule 8.4.d: Warrants (2016-3 employee incentive program), cf. Article 8.4 of the Articles of Association.

 

 

 

20.8          Bilag 8.4.e: Warrants (2017-1 employee incentive program), jf. vedtægternes § 8.4.

 

Schedule 8.4.e: Warrants (2017-1 employee incentive program), cf. Article 8.4 of the Articles of Association.

 

 

 

20.9          Bilag 8.4.i: Warrants (2018-1 employee incentive program), jf. vedtægternes § 8.4.

 

Schedule 8.4.i: Warrants (2018-1 employee incentive program), cf. Article 8.4 of the Articles of Association.

 

 

 

20.10   Bilag 8.4.k: Warrants (2018-2 employee incentive program), jf. vedtægternes § 8.4.

 

Schedule 8.4.k: Warrants (2018-2 employee incentive program), cf. Article 8.4 of the Articles of Association.

 

 

 

- 0 -

 

- 0 -

 

 

 

Vedtaget på bestyrelsesmøde afholdt den 10 april 2019.

 

Approved at the Board meeting held on 10 April 2019.

 


EX-99.1 3 a19-8906_1ex99d1.htm EX-99.1

Exhibit  99.1

 

 

Company announcement — No. 14 / 2019

 

Zealand Pharma announces amendments to its Articles of Association following the granting of warrants

 

Copenhagen, April 17, 2019 — Zealand Pharma (“Zealand”) announces that its Articles of Association have been amended to reflect the recent grant of warrants to the Company’s employees, as announced in Company Announcement no. 13/2019 on April 10, 2019.

 

The warrant program is an incentive scheme reflecting Zealand’s objective to attract and retain first-rate employees and help ensure shared short- and long-term interests for the management, employees and shareholders of the Company.

 

The amendments to Zealand’s Articles of Association entailed by the share capital increase have been registered today with the Danish Business Authority.

 

For further information, please contact:

 

Adam Steensberg, Interim Chief Executive Officer,
Executive Vice President and Chief Medical & Development Officer
Tel: +45 50 60 36 01, e-mail: ast@zealandpharma.com

 

Mats Blom, Executive Vice President, Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

 

About Zealand Pharma A/S

 

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

 

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

 


GRAPHIC 4 g89061mmi001.jpg GRAPHIC begin 644 g89061mmi001.jpg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end